Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Intellipharmaceutics International Inc V.IPCI.H

Alternate Symbol(s):  IPCIQ

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.


TSXV:IPCI.H - Post by User

Post by Nogah3on Jan 16, 2020 10:15pm
333 Views
Post# 30563294

Did you notice?

Did you notice?Hi all,

I spoke about this company's advancement (licensing out 3 drugs) for Q4 and its even greater potential which unfortunately the market does not understand. The final point I wished to raise awareness of was the price manipulation this morning.

There was one shareholder with >270K shares who entered extremely low ask prices this morning before market open. Of course, with the news that the the committee wasn't supporting the company's Oxycodone formulation, seeing ask prices in the range of 12 to 20 cents must have been devestating. I am sorry for those who felt pressured to sell by this malicious trick. That person gobbled hundreds of thousands of shares at a fifth of their value.

For the rest of you still holding shares, I would advise that you keep them and not listen to those who tell you to cut your losses. Why? Because as stated before, the company has made 3 recent signings that will grow revenue and this is not a company that has its eggs in one basket. PLUS, for those who went to the company's website to have a look at their pipeline, you'll notice that their real big gun (pregabalin, Market size >$5 Bil) is yet to come along with a few others in the making.

TL;DR -> hold your shares and you'll see the price slowly but surely rebound.
Take care
<< Previous
Bullboard Posts
Next >>